Shared on 06 Nov 25
Fair value Decreased 21%OSUR: Activist Pressure Will Drive Shareholder Value Amid Board Challenge
Analysts have revised their price target for OraSure Technologies from $6.00 to $4.75, citing updated projections for revenue growth and broader shifts in valuation estimates. What's in the News Healthcare entrepreneur Ron Zwanziger warned OraSure that he may pursue an adversarial strategy if the company continues to resist his acquisition bid, following OraSure's rejection of his all-cash offer earlier this summer (Reuters).
Shared on 31 Jul 25
With the consensus analyst price target and key valuation metrics such as the discount rate and future P/E ratio remaining effectively unchanged, analysts see little shift in OraSure Technologies’ fair value, which stays at $6.00. What's in the News Ron Zwanziger, supported by a Wall Street investor, made an unsolicited all-cash takeover offer for OraSure Technologies at $3.50-$4.00 per share, which the board rejected without discussions; this was Zwanziger’s second unsuccessful approach.
Shared on 23 Apr 25
Fair value Decreased 18%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 13%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 11 Mar 25
Fair value Increased 6.71%AnalystConsensusTarget has decreased revenue growth from -17.0% to -5.5% and decreased future PE multiple from 32.2x to 23.1x.